Get Access to Irinotecan liposome in India

Irinotecan liposome is considered an effective medication for the treatment of metastatic adenocarcinoma of the pancreas. This is a treatment option after the progression or failure of first line treatment, which is gemcitabine based. It is indicated as a combination therapy and therefore Irinotecan liposome can’t be treated as a single agent. Onivyde is the brand name of this drug. It is owned by the company Ipsen Biopharm Ltd. It was developed by Merrimack Pharmaceuticals. Irinotecan liposome in India can be procured from any of the countries it is available.

Onivyde is used in combination of drugs fluorouracil (5-FU) and leucovorin (LV). The settings are very specific in the patients with metastatic adenocarcinoma. It can’t be used for any other cancer treatment other than Ca Pancreas. However, it is also important to note the orphan drug designation it has received for the treatment of Small Cell Lung Cancer. The clinical study data shows the improved overall survival with this medicine. Often times this would be the only effective option for the pancreatic cancer patients in specific settings. It was approved in 2015 by the FDA. It is a topoisomerase inhibiter which explains its mechanism of action

Onivyde 43mg/10ml or Onivyde 4.3mg/ml is commercially available as single dose vials. It is given through intravenous route and is administered once in two weeks. The dosage specifics and duration of the treatment will be decided by the treating Oncologist. Recommending Onivyde in India is based on the need and awareness of the treating physicians regarding the access to such medications.